About Our Lab
The overarching goal of our research is to define the key molecular pathways in the pathogenesis of neurodegenerative diseases including Parkinson’s and Huntington’s disease. Using patient-derived induced pluripotent stem cells (iPSCs) differentiated into neurons, we study cellular dysfunction of endolysosomal and mitochondrial pathways in genetic models of Parkinson’s (α-synuclein, LRRK2, VPS35, ATP13A2, PINK1, parkin, DJ-1 and GBA1), as well as the cellular mechanisms involved in Huntington’s disease and Frontotemporal Dementia (FTD) pathogenesis. We aim to advance patient-specific approaches to therapeutic development, including development of new technologies for iPSCs to examine selective neuronal vulnerability. We focus on identification of converging pathogenic pathways to identify key targets for therapeutic development in neurodegenerative diseases such as Parkinson's. Learn more about the Krainc Lab
Wong, Y.C., Ysselstein, D., Krainc, D. Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydroloysis. Nature, 2018
Burbulla, L.F., Song, P., Mazzulli, J.R., Zampese, E., Wong, Y.C., Jeon, S., Santos, D.P., Blanz, J., Obermaier, C., Strojny, C., Savas, J., Kiskinis, E., Zhuang, X., Krüger, R., Surmeier, J.D., Krainc, D. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science, 2017
Trajkovic, K., Jeong, H. and Krainc, D. “Mutant huntingtin is secreted via a late endosomal/lysosomal unconventional secretory pathway.” Journal of Neuroscience, 2017
Wong, Y.C., and Krainc, D. “α-synuclein toxicity in neurodegeneration and therapeutic strategies.” Nature Medicine, 2016.
Mazzulli J.R., Zunke, F., Tsunemi, T., Toker, N.J., Jeon, S., Burbulla, L.F., Patnaik, S, Ellen Sidransky, E., Marugan, J., Sue, C., and Krainc, D. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Journal of Neuroscience, 2016